Jing Xu

VP and Head of Global Strategy at Sciwind Biosciences

Speaker

Jing Xu serves as VP and Head of Global Strategy at Sciwind Biosciences, leading corporate strategy and global business development. With a robust background that spans over a decade in the healthcare sector, Jing has held diverse positions, including senior executives, investor, as well as strategy and BD leader at LYFE, Amgen and WuXi. As Investment Principal at LYFE Capital, she was leading investments within pharmaceutical companies as well as pharma value chain across APAC region. Her extensive experience across the entire drug development lifecycle has enabled her to lead and actively support investments and portfolio management in notable portfolios such as MediLink, ProfoundBio, ST Pharm, Chemlex etc. Jing earned her PhD in Pharmaceutical Sciences from Northeastern University and holds a bachelor’s degree in Biology from Nanjing University.

Sciwind Biosciences is a biotechnology company focused on discovering and developing novel peptide- and antibody-based therapies for metabolic diseases. Leveraging proprietary technology platforms, we are advancing a robust pipeline anchored by our lead asset, Ecnoglutide (XW003), currently in the BLA stage in China. Our portfolio targets GLP-1 and synergistic mechanisms, offering both injectable and oral treatment solutions to deliver sustainable and high quality treatments for patients.